Zacks' 7 Best Stocks for June, 2013
FREE Report for Zacks.com
Visitors Only

They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.

Today, you can see them free.

Close This Panel X

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 05/24/2013

Company Name Symbol %Change
EAGLE BULK S EGLE
3.67%
UNIVL TRUCKL UACL
2.74%
PDI INC PDII
2.60%
A M R CP AAMRQ
1.79%
CGG VERITAS CGG
1.67%

Spherix, Inc.

June 28, 2010 | Comments : 0 Recommended this article: (0)

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Spherix, Inc. (SPEX) announced that it was shifting focus on the company s phase III candidate from type-2 diabetes to triglyceride lowering. This may come as a surprise to some Spherix investors; however, the strategy move makes sense to us considering the bar moved significant higher for approval of new type-2 diabetes drugs following the new FDA guidelines on cardiovascular safety established in March 2008.

This was after Spherix has already designed the current phase III protocol. The new path to market for triglycerides will be cheaper and quicker for the company. In the meantime, Spherix will look to partner D-tagatose for type-2 diabetes with a larger pharmaceutical organization. This partnership becomes more likely after the phase III NEET data is released later this summer.

Read the full reports :

Email Print Share Rate Pos Rate Neg

Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.